PT  - JOURNAL ARTICLE
AU  - Tyler KT Smith
AU  - Zaina Kahiel
AU  - Nicholas D LeBlond
AU  - Peyman Ghorbani
AU  - Eliya Farah
AU  - Marceline Cote
AU  - Suresh Gadde
AU  - Morgan D Fullerton
TI  - Characterization of LXR-activating nanoparticle formulations in primary mouse macrophages
AID  - 10.1101/746784
DP  - 2019 Jan 01
TA  - bioRxiv
PG  - 746784
4099  - http://biorxiv.org/content/early/2019/08/25/746784.short
4100  - http://biorxiv.org/content/early/2019/08/25/746784.full
AB  - Activation of the transcription factor liver X receptor (LXR), has shown to be efficient at curbing aberrant lipid metabolism and inflammation. While small molecule delivery via nanomedicine has promising applications for a number of chronic diseases, there remain questions as to how nanoparticle formulation might be tailored to suit different tissue microenvironments and aid in drug delivery. In the current study, we compared the drug delivery capability of three nanoparticle (NP) formulations encapsulating the LXR activator, GW-3956. We observed little difference in the base characteristics of standard PLGA-PEG NP when compared to two redox-active polymeric NP formulations (DD and DB). Moreover, we also observed similar uptake of these NP into primary mouse macrophages. After an initial acute uptake period and using the transcript and protein expression of the cholesterol efflux protein ATP binding cassette A1 (ABCA1) as a readout, we determined that while the induction of transcript expression was similar between NPs, treatment with the redox-sensitive DB formulation resulted in a higher level of ABCA1 protein 24 h after the removal of the drug-containing NPs. Our results suggest that NP formulations responsive to cellular cues may be an effective tool for targeted and disease-specific drug release.